Aprela (bazedoxifene and conjugated estrogens; Pfizer)
未來預測的假設
2010-2020年間的預測
SMC021 (salmon calcitonin; Novartis)
未來預測的假設
2010-2020年間的預測
Ostora (salmon calcitonin; Tarsa)
未來預測的假設
2010-2020年間的預測
NBS101 (strontium malonate; Servier/Osteologix)
未來預測的假設
2010-2020年間的預測
第6章 參考文獻
雜誌
網站
Datamonitor報告
第7章 附錄
目錄
Description
Introduction
Despite major brands losing market exclusivity increasing generic competition, the osteoporosis market remains attractive. Over the forecast period (2010-20), Datamonitor forecasts nine pipeline products to launch across the seven major markets. These candidates will drive growth in this therapy area by addressing compliance, safety and efficacy unmet needs.
Features and benefits
Evaluate a highly granular forecast with sales value projections to 2020 at the country, class, molecule, and product level.
Determine the impact of generics and pipeline products on existing brands
Quantify the sales potential for new osteoporosis treatments.
Highlights
The osteoporosis market will grow over the forecast period across the seven major markets reaching $9.2bn in 2020 from $6.6bn in 2010 with a compound annual growth rate (CAGR) during 2010-20 of 3.3%. Growth will be driven by the launch of novel pipeline products which will address market unmet needs.
The antiresorptive class of drugs is by far the largest in the market, accounting for an estimated 90% of the total sales in 2010. The uptake of novel antiresorptives Prolia (Amgen/GlaxoSmithKline/Daiichi Sankyo) and odanacatib (Merck & Co) will offset the fierce class generic erosion as all major brands prepare to lose patent protection from 2012.
The largest opportunity is for novel bone building therapies. The class is currently underserved with just the PTH and analogs offering a purely anabolic effect and this will remain the case at the end of the forecast period. Datamonitor forecasts Zosano's, Zelos's and Radius's PTH candidates to launch with combined forecast sales of $966m in 2020.
Your key questions answered
What will the overall osteoporosis market dynamics be over the next 10 years?
How will odanacatib perform upon launch?
How will Prolia's uptake develop over the next 10 years
What countries will show the greatest growth and why?
TOC
Executive Summary
Strategic scoping and focus
Datamonitor key findings
Related reports
OVERVIEW
Catalyst
Summary
MARKET DEFINITION
Market definition for this disease
Forecast methodology and assumptions
Patent expiries
New product launches
Additional forecast methodology
MARKET OVERVIEW AND CONTEXT
Current and future market dynamics overview
The osteoporosis market will display growth following the launch of promising pipeline products
Sales of pipeline products will account for 39% of revenue in 2020
Anabolic drugs will drive market growth but antiresorptives will continue to account for the largest share of sales
Bisphosphonates will remain the largest class but will lose market share and will not display growth
US
Sales will grow to reach $4.2bn in 2020
Japan
New drug launches will help to develop the market
France
Pipeline launches offset generic erosion driving sales to reach $476m in 2020
Germany
Osteoporosis sales will display minimal growth up to 2020
Italy
Sales in Italy will continue to grow to 2020 reaching $615m
Spain
Anabolic treatments will continue to drive growth
UK
Sales in the UK will remain very small compared to the rest of the major EU markets
PRODUCT FORECASTS
Fosamax/Fosamax Plus D (alendronate; Merck & Co.) in osteoporosis
Forecast assumptions
Fosamax/Fosamax Plus D forecast 2010-20
Actonel/Actonel with Calcium/Atelvia (risedronate; Sanofi/Warner Chilcott) in osteoporosis
Forecast assumptions
Actonel/Actonel with Calcium/Atelvia forecast 2010-20
Bonviva/Boniva (ibandronic acid; Roche/GlaxoSmithKline) in osteoporosis
Forecast assumptions
Bonviva/Boniva forecast 2010-20
Aclasta/Reclast (zoledronic acid; Novartis) in osteoporosis
Forecast assumptions
Aclasta/Reclast forecast 2010-20
Forteo (teriparatide; Eli Lilly) in osteoporosis
Forecast assumptions
Forteo forecast 2010-20
Prolia (denosumab; Amgen/GlaxoSmithKline/Daiichi Sankyo) in osteoporosis
Forecast assumptions
Prolia forecast 2010-20
Evista (raloxifene; Eli Lilly) in osteoporosis
Forecast assumptions
Evista forecast 2010-20
Conbriza/Viviant (bazedoxifene; Pfizer/Almirall) in osteoporosis
Forecast assumptions
Conbriza/Viviant forecast 2010-20
Protelos (strontium ranelate; Servier) in osteoporosis
Forecast assumptions
Protelos forecast 2010-20
Edirol (eldecalcitol; Chugai/Taisho) in osteoporosis
Forecast assumptions
Edirol forecast 2010-20
Odanacatib (MK-0822; Merck & Co.) in osteoporosis
Forecast assumptions
Odanacatib forecast 2010-20
ZT-031 (hPTH1-31; Zelos Therapeutics) in osteoporosis
Forecast assumptions
ZT-031 forecast 2010-20
ZP-PTH (hPTH1-34; Zosano Pharma) in osteoporosis
Forecast assumptions
ZP-PTH forecast 2010-20
BA058 (PTH peptide fragment; Radius) in osteoporosis
Forecast assumptions
BA058 forecast 2010-20
EX101 (alendronate; EffRx/Nycomed) in osteoporosis
Forecast assumptions
EX101 forecast 2010-20
Aprela (bazedoxifene and conjugated estrogens; Pfizer) in osteoporosis
Forecast assumptions
Aprela forecast 2010-20
SMC021 (salmon calcitonin; Novartis) in osteoporosis
Forecast assumptions
SMC021 forecast 2010-20
Ostora (salmon calcitonin; Tarsa) in osteoporosis
Forecast assumptions
Ostora forecast 2010-20
NBS101 (strontium malonate; Servier/Osteologix) in osteoporosis
